

Hafnarfjordur and Zug, 27 April 2012

Mr. John Dalli, Commissioner for European Health and Consumer Policy  
Mr. Nils Behrndt, Deputy Head of Cabinet

Dear Mr. Dalli and Mr. Behrndt

**Subject: Comments on the Concept Paper on the Delegated Act for a Unique Identifier for Medicinal Products for Human Use, and its Verification and on the implementation of key API quality and GMP aspects the EU Falsified Medicines Directive**

Actavis supports the European Union in their fight against counterfeit and falsified medicines. However we would like to point out that the real public health problem and threat to patients lies in falsified and counterfeit medicines being dispensed through illegal channels, mainly the internet. There are no reports of counterfeit generic medicines in the EU at all and especially not in the legal supply chain.

Actavis wishes to confirm that we strongly support the EGA position papers on

- Concept Paper on the Delegated Act for A Unique Identifier for Medicinal Products for Human Use and
- EGA White Paper on the Implementation of Key API Quality and GMP Aspects of the EU falsified Medicines Directive (2011/62/EU)

Yours sincerely,



Gudbjorg Edda Eggertsdottir,  
President,  
Iceland & Strategic Projects